Morgan Stanley Reinstates Equal-Weight on Edwards Lifesciences, Announces $70 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Patrick Wood has reinstated an Equal-Weight rating on Edwards Lifesciences (NYSE:EW) and set a price target of $70.
October 11, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley has reinstated an Equal-Weight rating on Edwards Lifesciences with a $70 price target, indicating a neutral stance on the stock.
The reinstatement of an Equal-Weight rating by Morgan Stanley suggests a neutral outlook on Edwards Lifesciences, with the $70 price target indicating no significant upside or downside expected in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100